PubRank

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients (ENDEAVOR)

Clinical Trial ID NCT01568866

PubWeight™ 20.59‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01568866

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2015 2.44
2 Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 2013 1.84
3 Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013 1.76
4 Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia 2016 1.43
5 Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets 2014 1.29
6 Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol 2013 1.04
7 A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood 2014 0.91
8 Promising therapies in multiple myeloma. Blood 2015 0.89
9 Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib. Blood Cancer J 2015 0.83
10 Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant 2016 0.82
11 Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharmgenomics Pers Med 2015 0.82
12 From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma. Ther Adv Hematol 2013 0.81
13 Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. Biomed Res Int 2015 0.81
14 Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer 2014 0.80
15 CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood 2016 0.79
16 Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med 2015 0.76
17 Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. Leuk Lymphoma 2017 0.75
18 Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes. Leukemia 2017 0.75
19 A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma. Ther Adv Hematol 2016 0.75
20 The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. Adv Ther 2016 0.75
21 American Society of Hematology 2015 Annual Meeting. P T 2016 0.75
22 Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway. J Clin Oncol 2015 0.75
23 Salvage therapy of multiple myeloma: the new generation drugs. Biomed Res Int 2014 0.75
24 Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials. Int J Hematol 2019 0.75
25 Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. Leukemia 2016 0.75
26 Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017 0.75
27 Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J 2016 0.75
Next 100